<?xml version="1.0" encoding="UTF-8"?>
<p>The development of a novel downstream process and the successful production of NVCP VLPs that meet all regulatory release specifications in identity, purity, potency, and safety by our group provide an additional step for NoV VLP vaccines to become a commercial reality [
 <xref ref-type="bibr" rid="CR0008126">126</xref>]. These successes have demonstrated the potential and feasibility of VLPs as NoV vaccines and suggest they can serve as an excellent model for developing effective strategies of mucosal immunization with non-replicating antigens.
</p>
